MedTrace Logo

Anti-psychotic Medication (Stable Dose) Weight Loss Study

NCT01272765 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-06-01

No results posted yet for this study

Summary

This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have been taking a stable dose of certain anti-psychotic medications for longer than three months.

Conditions

Interventions

OTHER

Placebo

Placebo

DIETARY_SUPPLEMENT

IHBG-10

500 mg IHBG-10

Sponsors & Collaborators

  • Avera McKennan Hospital & University Health Center

    lead OTHER

Principal Investigators

  • Edward Zawada, MD · Avera McKennan Hospital & University Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272765 on ClinicalTrials.gov